Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Indirect treatment comparison of belantamab mafodotin + pomalidomide + dexamethasone versus comparator regimens in lenalidomide-exposed relapsed/refractory multiple myeloma: A network meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAlessandro CorsoJBJacopo BitettiBKBenga Kazeem

Discussion

Loading...

Member takes

Overview

Network meta-analysis highlights increased progression-free survival with belantamab mafodotin plus pomalidomide in len-exposed multiple myeloma patients.

Key Points

  • Progression-free survival was significantly improved with pomalidomide and dexamethasone compared to several comparator regimens.
  • The network meta-analysis included results from randomized controlled trials, revealing treatment effects favoring belantamab mafodotin.
  • Analysis using credible intervals indicated a strong likelihood that treatment effects were beneficial for belantamab mafodotin.
  • These findings may enhance therapeutic strategies for managing relapsed/refractory multiple myeloma in patients previously treated with lenalidomide.

Cite This Study

Corso et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d62chttps://doi.org/10.1182/blood-2025-7567
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study2025 · 4 citations
  2. 2Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis2025
  3. 3Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change2025
  4. 4Life-years and quality-adjusted life-years with belantamab mafodotin, bortezomib, and dexamethasone vs alternative regimens in patients with Relapsed/Refractory multiple myeloma who received ≥1 prior line of therapy2025
  5. 5Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial2025 · 1 citations